Deng Minying, Luo Rongkui, Chen Lingli, Wang Huimei, Huang Wen, Song Qi, Jiang Dongxian, Xu Lei, Su Jieakesu, Xu Chen, Hou Yingyong
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Am J Surg Pathol. 2025 Jul 1;49(7):711-729. doi: 10.1097/PAS.0000000000002393. Epub 2025 Apr 7.
Carboxypeptidase Z (CPZ) is a newly identified member of the metallopeptidase family, primarily reported in rats; however, its distribution in normal human tissues and expression characteristics in tumor tissues remain unclear. This study uses high-throughput and mass production technology for tissue microarray (TMA) to perform immunohistochemical staining of CPZ, for the first time delineating its distribution and expression in normal tissues and various tumors throughout the body, to discuss its potential pathologic value. CPZ exhibited varying degrees of cytoplasmic positive expression in the normal hepatocytes, pancreatic islets, and gallbladder epithelium, with no expression observed in other normal tissues. The positive expression rates of CPZ in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), metastatic liver tumors, and normal liver tissue were 90.8% (109/120), 27.7% (13/47), 0% (0/22), and 100% (81/81), respectively. The sensitivity and specificity for diagnosing HCC with any of the 3 markers (CPZ, arginase-1 (Arg-1), and hepatocyte paraffin antigen-1 (Hep Par-1)) positive were 96.7% (116/120) and 65.2% (45/69), respectively. The sensitivity and specificity for diagnosing HCC with all 3 markers positive were 70.8% (85/120) and 100% (69/69), respectively. The sensitivity and specificity for diagnosing HCC with both CPZ and Arg-1 positive were 79.2% (95/120) and 95.7% (66/69), respectively. The sensitivity and specificity for diagnosing HCC with both CPZ and Hep Par-1 positive were 76.7% (92/120) and 97.1% (67/69), respectively. The sensitivity and specificity for diagnosing HCC with both Arg-1 and Hep Par-1 positive were 72.5% (87/120) and 98.6% (68/69), respectively. The ROC curve indicated that the combined detection of CPZ, Arg-1, and Hep Par-1 had the best diagnostic value for HCC (AUC=0.939, P <0.001). However, for individual detection, CPZ had the highest AUC value among the 3 markers (AUC=0.908, P <0.001). CPZ was not observed to be positive in the majority of 897 cases of solid tumors. Utilizing the TMA repository, we propose for the first time that CPZ may serve as a useful adjunctive tool for the diagnosis or differential diagnosis of HCC in routine surgical pathology practice. CPZ shows a trend of superiority over Arg-1 and Hep Par-1, particularly in poorly differentiated HCC.
羧肽酶Z(CPZ)是金属肽酶家族新发现的成员,最初在大鼠中报道;然而,其在正常人体组织中的分布以及在肿瘤组织中的表达特征仍不清楚。本研究采用组织微阵列(TMA)的高通量和大规模生产技术对CPZ进行免疫组织化学染色,首次描绘其在全身正常组织和各种肿瘤中的分布及表达情况,以探讨其潜在的病理价值。CPZ在正常肝细胞、胰岛和胆囊上皮细胞中呈现不同程度的细胞质阳性表达,在其他正常组织中未观察到表达。CPZ在肝细胞癌(HCC)、肝内胆管癌(ICC)、转移性肝肿瘤和正常肝组织中的阳性表达率分别为90.8%(109/120)、27.7%(13/47)、0%(0/22)和100%(81/81)。三种标志物(CPZ、精氨酸酶-1(Arg-1)和肝细胞石蜡抗原-1(Hep Par-1))中任一项阳性诊断HCC的敏感性和特异性分别为96.7%(116/120)和65.2%(45/69)。三种标志物均阳性诊断HCC 的敏感性和特异性分别为70.8%(85/120)和100%(69/69)。CPZ和Arg-1均阳性诊断HCC的敏感性和特异性分别为79.2%(95/120)和95.7%(66/69)。CPZ和Hep Par-1均阳性诊断HCC的敏感性和特异性分别为76.7%(92/120)和97.1%(67/69)。Arg-1和Hep Par-1均阳性诊断HCC的敏感性和特异性分别为72.5%(87/120)和98.6%(68/69)。ROC曲线表明,联合检测CPZ、Arg-1和Hep Par-1对HCC具有最佳诊断价值(AUC=0.939,P<0.001)。然而,对于单项检测,CPZ在三种标志物中AUC值最高(AUC=0.908,P<0.001)。在897例实体瘤的大多数病例中未观察到CPZ呈阳性。利用TMA库,我们首次提出CPZ可能作为常规外科病理实践中HCC诊断或鉴别诊断的有用辅助工具。CPZ显示出优于Arg-1和Hep Par-1的趋势,尤其是在低分化HCC中。